共 102 条
[1]
Casali PG(2010)Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 198-203
[2]
Blay JY(2010)Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years Ann Oncol 22 1266-1272
[3]
Penel N(1997)Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 35-61
[4]
Van Glabbeke M(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996
[5]
Marreaud S(2005)MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997-1003
[6]
Ouali M(2005)A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas Cancer 104 1706-1712
[7]
Blay JY(1999)Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 35 410-412
[8]
Hohenberger P(2009)Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma Int J Radiat Oncol Biol Phys 75 810-816
[9]
Newlands ES(2000)Predicting lung cancer by detecting aberrant promoter methylation in sputum Cancer research 60 5954-5958
[10]
Stevens MF(2009)Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy Br J Cancer 101 124-131